These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy. McMahon CG Int J Impot Res; 2003 Oct; 15(5):383-4. PubMed ID: 14562142 [No Abstract] [Full Text] [Related]
7. Intraurethral alprostadil for impotence. Med Lett Drugs Ther; 1997 Mar; 39(997):32. PubMed ID: 9121395 [No Abstract] [Full Text] [Related]
8. Intracorporeal phenylephrine in the treatment of priapism. Muruve N; Hosking DH J Urol; 1996 Jan; 155(1):141-3. PubMed ID: 7490814 [TBL] [Abstract][Full Text] [Related]
9. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. Rooney M; Pfister W; Mahoney M; Nelson M; Yeager J; Steidle C J Sex Med; 2009 Feb; 6(2):520-34. PubMed ID: 19138370 [TBL] [Abstract][Full Text] [Related]
10. [Management of priapism induced by PGE1]. Guzman Martínez-Valls PL; Tomas Ros M; Ferrero Doria R; Morga Egea JP; Navas Pastor J; Rico Galiano JL; Sempere Gutierrez A; Fontana Compiano LO Arch Esp Urol; 1998 Jun; 51(5):457-60. PubMed ID: 9675941 [TBL] [Abstract][Full Text] [Related]
12. [Comment on the contribution by H. Porst and H. van Ahlen. Drug-induced priapism--a report of experiences with 101 cases. Urologe [A] (1989) 28: 84-7]. Rudnick J Urologe A; 1989 Nov; 28(6):367. PubMed ID: 2603283 [No Abstract] [Full Text] [Related]
13. The incidence and management of priapism in Western Australia: a 16 year audit. Earle CM; Stuckey BG; Ching HL; Wisniewski ZS Int J Impot Res; 2003 Aug; 15(4):272-6. PubMed ID: 12934055 [TBL] [Abstract][Full Text] [Related]
15. [Priapism after intracavernous injection of PgE1 in two cases of impotence following total cysto-prostatectomy]. Llopis J; Romero JA; Gutiérrez R; Alvarez R; Talbot R; Vendrell JR; Barranco MA; Carretero P J Urol (Paris); 1995; 101(2):104-6. PubMed ID: 8522852 [TBL] [Abstract][Full Text] [Related]
16. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1. Buvat J; Lemaire A; Herbaut-Buvat M Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388 [TBL] [Abstract][Full Text] [Related]
17. [Iatrogenic priapism caused by intracavernous injection of vasoactive drugs in the treatment of impotence]. Bondil P Presse Med; 1986 Apr; 15(14):665. PubMed ID: 2939440 [No Abstract] [Full Text] [Related]
18. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184 [TBL] [Abstract][Full Text] [Related]
19. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. Seyam R; Mohamed K; Akhras AA; Rashwan H Int J Impot Res; 2005; 17(4):346-53. PubMed ID: 15772683 [TBL] [Abstract][Full Text] [Related]
20. Deep venous thrombosis and venous thrombophlebitis associated with alprostadil treatment for erectile dysfunction. Barthelmes L; Chezhian C; Aihaku EK Int J Impot Res; 2002 Jun; 14(3):199-200. PubMed ID: 12058249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]